Health ❯Healthcare ❯Drug Development

Clinical Trials

FDA Approval Amyloid Immunotherapy Epinephrine Alternatives Tumor-Infiltrating Lymphocytes Alzheimer's Disease Treatments Regulatory Exclusivity Biosimilar Approval Process Leqembi Innovative Therapies GBT-601 Pharmaceutical Innovations Alzheimer's Disease Neuropharmacology Neurodegenerative Diseases Randomized Controlled Trials Market Dynamics Real-World Evidence AI in Medicine CAPLYTA Late-Stage Studies Eli Lilly Weight-loss Medications

Johnson & Johnson to Acquire Intra-Cellular Therapies in $14.6 Billion Deal

Alberta Signs $162M Deal to Expand Access to Rare Disease Drugs

Ozempic and Wegovy Now Available After Prolonged Shortages

Breakthrough Alzheimer's Drug Targets Key Tau Protein Hotspots

Pfizer Withdraws Sickle Cell Drug Oxbryta Over Safety Concerns

Pioneers of Obesity Drugs Win Prestigious Lasker Award

UCLA Researchers Develop Molecule That Restores Memory in Alzheimer's Model Mice

FDA Approves Neffy: First Needle-Free Epinephrine Nasal Spray for Allergic Reactions

New Alzheimer's Drugs Face Scrutiny Over Efficacy and Safety